Aprea Therapeutics closes oversubscribed $30M private placement to fund APR-1051 development

Aprea Therapeutics, Inc.

Closed oversubscribed $30M private placement on March 31, 2026; proceeds for R&D and general corporate.
Proceeds to accelerate APR-1051 development, targeting uterine serous carcinoma and platinum-resistant ovarian cancer with 50+ patients.
Offering led by Soleus Capital; included pre-funded warrants at ~$0.807/sh and warrants at $0.683/sh, expiring Dec 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.